Altoida is a health technology firm that uses digital biomarkers to drive better clinical outcomes for brain diseases. Led by a team of esteemed neuroscientists, physicians and computer scientists, the company offers a FDA and CE Mark-cleared medical device and brain health data platform to support early detection of Alzheimer’s disease up to ten years prior to onset – with up to 94% accuracy. The company is headquartered in Houston, TX, and has offices in San Diego, CA, and Lucerne, Switzerland.

Team Member
more about
Therese Liechtenstein
Latest News Entry
Altoida Unveils New Brand Identity with Reimagined Logo and Website

Refreshed brand identity reflects Altoida’s emphasis on data and humanity, and will support the company’s growth as the world leader in Precision Neurology

Altoida raises $6.3m Series A to Predict Alzheimer’s Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality

New digital biomarkers company secures $6.3 MM in venture capital to detect Alzheimer’s disease 6-10 years prior to onset of Mild Cognitive Impairment (MCI) symptoms - with up to 94% accuracy

all portfolio news